Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil

Rhea-AI Summary

Relief Therapeutics reported that its partner, NRx Pharmaceuticals, has established a regulatory pathway with Hungarian Health Officials for the emergency use of aviptadil. This program is expected to commence by the end of 2021. Relief is focused on clinical-stage programs, notably advancing RLF-100 (aviptadil) for COVID-19 related respiratory issues. The company also diversifies its pipeline through agreements like the one with Acer Therapeutics for ACER-001 aimed at treating Urea Cycle Disorders.

Positive

• Regulatory agreement for aviptadil with Hungarian officials supports drug's emergency use.
• Advancement of RLF-100 in late-stage clinical testing enhances market position.
• Collaboration with Acer Therapeutics for ACER-001 expands pipeline opportunities.

Negative

• Dependence on regulatory approvals for aviptadil's market entry.
• Implementation of compassionate care program may indicate limited immediate market access.

GENEVA, SWITZERLAND / ACCESSWIRE / December 10, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc. (NRXP) ("NRx"), has announced it has agreed with Hungarian Health Officials on a regulatory path for emergency use of aviptadil in the Central European region, beginning with a compassionate care program, expected to begin by the end of 2021. The related NRx press release can be accessed through the following link.

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100(TM) (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn.

CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether aviptadil will ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients with COVID-19, and (ii) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG

View source version on accesswire.com:
https://www.accesswire.com/676959/Relief-Reports-that-its-US-Collaboration-Partner-has-Agreed-with-Hungarian-Health-Officials-on-a-Pathway-for-Aviptadil

FAQ

What is the significance of the recent Relief Therapeutics press release on aviptadil?

The press release highlights the regulatory agreement with Hungarian officials for aviptadil's emergency use, marking a critical step for Relief's lead drug in addressing COVID-19.

When is the compassionate care program for aviptadil expected to start?

The compassionate care program for aviptadil is expected to begin by the end of 2021.

What are Relief Therapeutics' key drug candidates mentioned in the press release?

Key drug candidates include RLF-100 (aviptadil) for COVID-19 and ACER-001 for treating Urea Cycle Disorders.

How does the collaboration with Acer Therapeutics impact Relief Therapeutics?

The collaboration with Acer Therapeutics allows Relief to diversify its pipeline with ACER-001, enhancing its long-term growth prospects.

What stocks are associated with Relief Therapeutics?

Relief Therapeutics is traded on the SIX under the symbol RLF and in the US on OTCQB under RLFTF and RLFTY.